Oxytrex™ is an investigational drug, a strong opioid painkiller with minimal physical dependence intended for patients with severe chronic pain. Pain Therapeutics today announced that it will present results from prior Phase III studies evaluating the safety, efficacy and minimal physical dependence of Oxytrex. These clinical trial results will be presented at the 25th Annual Scientific Meeting of the American Pain Society on May 4-5th in
Nadav Friedmann, PhD, MD, chief operating and medical officer of Pain Therapeutics strongly stated that the collective results of the study supports the ongoing development program for Oxytrex, which would be sufficient to advance into a Phase III pivotal program in the second half of 2006.
Source: PTIE Press Release
.jpg)
Comment Preview